Lead HuR program now in Phase 1— first-in-class molecular glue degrader targeting previously undruggable RNA-binding protein intended to treat multiple types of solid tumors Degron Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results